Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingo J Diel

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Future Oncology (London, England)|March 25, 2006
Ibandronate: efficacy in the treatment of metastatic bone diseaseIngo J Diel
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 30, 2007
Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a reviewIngo J Diel
Breast Care (Basel, Switzerland)|July 23, 2011
Bisphosphonates in Breast Cancer Patients with Bone MetastasesIngo J Diel
The Journal of Supportive Oncology|February 5, 2008
Adverse effects of bisphosphonates: current issuesIngo J Diel, Raoul Bergner, Knut A Grötz
Onkologie|October 28, 2006
Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone diseaseRaoul Bergner, Ingo J Diel, Dirk Henrich, et al.
Anticancer Research|June 9, 2016
Management of Metastatic Bone Disease Algorithms for Diagnostics and TreatmentChristian F Jehn, Ingo J Diel, Friedrich Overkamp, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 13, 2010
Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance studyIngo J Diel, Andreas H A Kurth, Hans-Bernd Sittig, et al.
Annals of Surgical Oncology|December 25, 2012
Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up studyChristoph Domschke, Ingo J Diel, Stefan Englert, et al.
International Journal of Cancer|November 28, 2002
Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivoLianhua Bai, Philipp Beckhove, Markus Feuerer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 18, 2008
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records reviewIngo J Diel, Rudolf Weide, Hubert Köppler, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Future Oncology (London, England)|March 25, 2006
Ibandronate: efficacy in the treatment of metastatic bone diseaseIngo J Diel
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 30, 2007
Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a reviewIngo J Diel
Breast Care (Basel, Switzerland)|July 23, 2011
Bisphosphonates in Breast Cancer Patients with Bone MetastasesIngo J Diel
The Journal of Supportive Oncology|February 5, 2008
Adverse effects of bisphosphonates: current issuesIngo J Diel, Raoul Bergner, Knut A Grötz
Onkologie|October 28, 2006
Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone diseaseRaoul Bergner, Ingo J Diel, Dirk Henrich, et al.
Anticancer Research|June 9, 2016
Management of Metastatic Bone Disease Algorithms for Diagnostics and TreatmentChristian F Jehn, Ingo J Diel, Friedrich Overkamp, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 13, 2010
Bone pain reduction in patients with metastatic breast cancer treated with ibandronate-results from a post-marketing surveillance studyIngo J Diel, Andreas H A Kurth, Hans-Bernd Sittig, et al.
Annals of Surgical Oncology|December 25, 2012
Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up studyChristoph Domschke, Ingo J Diel, Stefan Englert, et al.
International Journal of Cancer|November 28, 2002
Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivoLianhua Bai, Philipp Beckhove, Markus Feuerer, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 18, 2008
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records reviewIngo J Diel, Rudolf Weide, Hubert Köppler, et al.
Pageof 2